On Monday 7 February, three million doses of the Nuvaxovid vaccine touched down at Sydney Airport on a flight from Singapore. The shipment was the first in an order of 51 million doses.

The delivery was in preparation for Nuvaxovid’s release on 15 February, which saw vaccination centres, pharmacies, and GP offices take possession of the new vaccine.

The protein vaccine (for more information, turn to page 32) could prove a boon for those unable or unwilling to take an mRNA vaccine, as it is made in a more ‘traditional’ style from synthesized COVID-19 spike proteins, attached to a fatty (lipid) nanoparticle.

Novavax is provisionally approved by the Therapeutic Goods Administration for use by adults as a primary course of vaccination, however it is not yet approved for booster shots.